Search clinical trials for: NGR-hTNF

Total 1354 results

National Cancer Institute (NCI)

Recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Intrahepatic Cholangiocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory...

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Grade 1 Meningioma | Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma | Unresectable Meningioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Hypopharyngeal... and other conditions

United States
Jonsson Comprehensive Cancer Center

Withdrawn

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Ductal Adenocarcinoma

United States
Children's Oncology Group

Not yet recruiting

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Central Nervous System Germinoma | Diabetes Insipidus | Pineal Region Germinoma | Suprasellar Germinoma
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma

Central Nervous System Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Suspended

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Adult Ovarian Granulosa Cell Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditions

United States, Canada
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
Mayo Clinic

Recruiting

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

Glioblastoma

United States
National Cancer Institute (NCI)

Recruiting

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia
Mayo Clinic
National Cancer Institute (NCI); United States Department of Defense

Recruiting

68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer

Hepatocellular Carcinoma

United States
University of Kansas Medical Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Recruiting

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Fred Hutchinson Cancer Center
Affini-T Therapeutics, Inc.

Recruiting

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Metastatic Colorectal Adenocarcinoma | Stage IV Lung Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8

United States
Fred Hutchinson Cancer Center
PromiCell Therapeutics, Inc.

Not yet recruiting

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Mayo Clinic

Recruiting

Blood-Based Biomarkers to Inform Treatment and Radiation Therapy Decisions for HPV Associated Oropharyngeal Squamous Cell Head and Neck Cancers

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal Human Papillomavirus-Positive Squamous...

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Metastatic NUT Carcinoma | Unresectable NUT Carcinoma | Advanced NUT Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI); AbbVie

Withdrawn

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Richter Syndrome | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Metastatic Merkel Cell Carcinoma | Metastatic Skin Squamous Cell Carcinoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Basal Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Unresectable... and other conditions

United States
Mayo Clinic

Completed

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

Hepatocellular Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma | Stage... and other conditions

United States, Canada, Hong Kong
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Lynch Syndrome | Stage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | DNA Repair Disorder

United States, Puerto Rico, Germany
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Not yet recruiting

Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent WHO Grade 4 Glioma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Medulloblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia
Abdullah Khan

Recruiting

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Hypopharyngeal Carcinoma AJCC v8 | Stage IV Laryngeal Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

AL Amyloidosis

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Squamous Carcinoma | Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8

United States, Guam

Search clinical trials for: NGR-hTNF

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations